Corvus Pharmaceuticals (CRVS) said late Thursday that new interim data from a phase 1 clinical trial of soquelitinib to treat moderate to severe atopic dermatitis showed a "favorable" safety and efficacy profile.
The company found "earlier and deeper responses" in group 3, which received 200 milligrams twice a day, compared with groups 1 and 2, which received 100 mg twice daily and 200 mg once daily.
Corvus said that all three groups showed "significant responses" in the soquelitinib treatment groups, compared with placebo for clinically significant endpoints.
Atopic dermatitis is a skin condition characterized by dry, itchy, and inflamed skin.
Shares of the company were up 37% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.